Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

DORYX MPC

×

Overview

What is DORYX MPC?

Doryx MPC (doxycycline hyclate delayed-release tablets) for oral use, contain doxycycline hyclate, a tetracycline class drug synthetically derived from oxytetracycline, in a delayed-release formulation consisting of pellets with a modified polymer enteric coat that has increased acid resistance.

The structural formula for doxycycline hyclate is:

with a molecular formula of CHNO, HCl, ½ CHO, ½ HO and a molecular weight of 512.9. The chemical name for doxycycline hyclate is [4S(4aR,5S,5aR,6R,12aS)]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-deoxonaphthacene-2-carboxamide monohydrochloride, compound with ethyl alcohol (2:1), monohydrate. Doxycycline hyclate is a yellow crystalline powder soluble in water and in solutions of alkali hydroxides and carbonates. Doxycycline has a high degree of lipid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form.

Each tablet contains doxycycline 60 mg or 120 mg (equivalent to doxycycline hyclate 69.4 mg or 138.8 mg). Inactive ingredients in the tablet formulation are: lactose monohydrate; microcrystalline cellulose; sodium lauryl sulfate; sodium chloride; talc; anhydrous lactose; corn starch; crospovidone; magnesium stearate; cellulosic polymer coating.

Each DORYX MPC 60 mg Tablet contains 3.6 mg (0.157 mEq) of sodium and each DORYX MPC 120 mg Tablet contains 7.2 mg (0.313 mEq) of sodium.



What does DORYX MPC look like?



What are the available doses of DORYX MPC?

DORYX MPC Delayed-Release Tablets: 60 mg, 120 mg

What should I talk to my health care provider before I take DORYX MPC?

How should I use DORYX MPC?

DORYX MPC is indicated for treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by .

Important Dosage and Administration Instructions:

Dosage in Adult Patients

Dosage in Pediatric Patients

See Full Prescribing Information for additional indication specific dosage information and important administration instructions for DORYX MPC. (, , )


What interacts with DORYX MPC?

Sorry No Records found


What are the warnings of DORYX MPC?

Sorry No Records found


What are the precautions of DORYX MPC?

Sorry No Records found


What are the side effects of DORYX MPC?

Sorry No records found


What should I look out for while using DORYX MPC?

DORYX MPC is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.


What might happen if I take too much DORYX MPC?

In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdosage.


How should I store and handle DORYX MPC?

Carton containing two epinephrine injection, USP auto-injectors 0.3 mg: NDC 54505-102-02.Carton containing one epinephrine injection, USP auto-injector 0.3 mg: NDC 54505-102-01.Carton containing two epinephrine injection, USP auto-injectors 0.15 mg: NDC 54505-101-02.Carton containing one epinephrine injection, USP auto-injector 0.15 mg: NDC 54505-101-01.Rx onlyCarton containing two epinephrine injection, USP auto-injectors 0.3 mg: NDC 54505-102-02.Carton containing one epinephrine injection, USP auto-injector 0.3 mg: NDC 54505-102-01.Carton containing two epinephrine injection, USP auto-injectors 0.15 mg: NDC 54505-101-02.Carton containing one epinephrine injection, USP auto-injector 0.15 mg: NDC 54505-101-01.Rx onlyCarton containing two epinephrine injection, USP auto-injectors 0.3 mg: NDC 54505-102-02.Carton containing one epinephrine injection, USP auto-injector 0.3 mg: NDC 54505-102-01.Carton containing two epinephrine injection, USP auto-injectors 0.15 mg: NDC 54505-101-02.Carton containing one epinephrine injection, USP auto-injector 0.15 mg: NDC 54505-101-01.Rx onlyCarton containing two epinephrine injection, USP auto-injectors 0.3 mg: NDC 54505-102-02.Carton containing one epinephrine injection, USP auto-injector 0.3 mg: NDC 54505-102-01.Carton containing two epinephrine injection, USP auto-injectors 0.15 mg: NDC 54505-101-02.Carton containing one epinephrine injection, USP auto-injector 0.15 mg: NDC 54505-101-01.Rx onlyCarton containing two epinephrine injection, USP auto-injectors 0.3 mg: NDC 54505-102-02.Carton containing one epinephrine injection, USP auto-injector 0.3 mg: NDC 54505-102-01.Carton containing two epinephrine injection, USP auto-injectors 0.15 mg: NDC 54505-101-02.Carton containing one epinephrine injection, USP auto-injector 0.15 mg: NDC 54505-101-01.Rx onlyDORYX MPC (doxycycline hyclate delayed-release tablets), 60 mg and 120 mg are white, oval tablets containing yellow pellets and debossed on one face with "D6" and "DC", respectively, and plain on the other. Each tablet contains doxycycline 60 mg or 120 mg (equivalent to doxycycline hyclate 69.4 mg or 138.8 mg).


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Doxycycline is a tetracycline-class antimicrobial drug [].

Non-Clinical Toxicology
DORYX MPC is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.

A.    Effect of Drugs and Other Agents on Cyclosporine Pharmacokinetics and/or Safety

All of the individual drugs cited below are well substantiated to interact with cyclosporine. In addition, concomitant use of nonsteroidal anti-inflammatory drugs with cyclosporine, particularly in the setting of dehydration, may potentiate renal dysfunction. Caution should be exercised when using other drugs which are known to impair renal function. (See )





During the concomitant use of a drug that may exhibit additive or synergistic renal impairment with cyclosporine, close monitoring of renal function (in particular serum creatinine) should be performed. If a significant impairment of renal function occurs, the dosage of the coadministered drug should be reduced or an alternative treatment considered.

Cyclosporine is extensively metabolized by CYP 3A isoenzymes, in particular CYP3A4, and is a substrate of the multidrug efflux transporter P-glycoprotein. Various agents are known to either increase or decrease plasma or whole blood concentrations of cyclosporine usually by inhibition or induction of CYP3A4 or P-glycoprotein transporter or both. Compounds that decrease cyclosporine absorption such as orlistat should be avoided. Appropriate cyclosporine [MODIFIED] dosage adjustment to achieve the desired cyclosporine concentrations is essential when drugs that significantly alter cyclosporine concentrations are used concomitantly. (See )

The use of drugs of the tetracycline-class during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the drugs but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. Use DORYX MPC in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g., anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies.

The following adverse reactions have been identified during post-approval use of doxycycline. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Due to oral doxycycline's virtually complete absorption, side effects to the lower bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines:

Gastrointestinal:

see

Skin:

see

Renal:

see

Hypersensitivity reactions:

Blood:

Intracranial Hypertension:

See

Thyroid Gland Changes:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).